MOLOGEN AG receives Orphan Drug status for cell based gene therapy for renal cancer. The Berlin-based biotechnology company MOLOGEN today announced that the European Commission has granted orphan drug status for MOLOGEN´s cell-based treatment for renal cancer. The European Commission hereby follows the recommendation of the European Agency for the Evaluation of Medical Products, EMEA, from September 2006.
